AN2 Therapeutics Shares Phase 3 EBO-301 Data and Future Milestones
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced...
Category : Clinical Research, Pharma & Healthcare Financing
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib...
Innovent Doses First Patient in Phase 1 Trial of IBI3020 ADC
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology...
FDA Approves VANRAFIA, Disrupting IgA Nephropathy Market
VANRAFIA (atrasentan), FDA-approved in April 2025, showed strong proteinuria reduction without REMS but carries similar safety warnings, requiring ongoing liver and pregnancy monitoring. However, its approval...
France Approves Illuccix PSMA-PET Imaging for Prostate Cancer
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that...
EU Grants Full Approval to FILSPARI for Treating IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation from Committee for...
Onc.AI to Present Breakthrough AI Model at AACR 2025
Serial CTRS (CT Response Score) improves prediction of overall survival compared to RECIST 1.1 and Tumor Volume Change in advanced NSCLC Onc.AI, a digital health...
Kardium Announces 1-Year Results for Globe® PF System
Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its...
OLYMPUS Study Reports 4-Year Response in Urothelial Cancer Patients
Data Presented at the 2025 American Urological Association Annual Meeting in Las Vegas, Nevada UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing...
Ray Therapeutics Gets $8M CIRM Grant for RP Gene Therapy
Funding will support ongoing clinical development of optogenetic therapy to restore vision Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, today...
CorWave Completes 6-Month Study, Eyes Clinical Trials
In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60...
Novo, EIFO Invest €48M in HealthCap to Boost Nordic Biotech
Novo Holdings and the Export and Investment Fund of Denmark (EIFO) have jointly invested €48 million in HealthCap IX, a Swedish life sciences venture fund focused on...
Cost Reduction is Top 2025 Priority for Benefits Decision Makers: Lockton Survey
Although 84% of plan sponsors see cost increases as their biggest challenge, more than half are unlikely to take proactive action. With U.S. healthcare costs...
AbolerIS Pharma Announces Formation of Scientific Advisory Board
AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of...
EmpiRx Health Partners with Giant Eagle to Transform Pharmacy Benefits Care
EmpiRx Health, the leading clinically-driven pharmacy benefits management (PBM) company that puts pharmacists at the center of its service model, today announced that Giant Eagle,...